FORM 10-KSB/A
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

[Mark One]
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

                    For the fiscal year ended: June 30, 2003

                                    or

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

            For the transition period from __________to_____________

                         Commission file number: 0-26028

                        IMAGING DIAGNOSTIC SYSTEMS, INC.
                 (Name of small business issuer in its charter)

                       Florida                 22-2671269
              (State of incorporation)  (IRS employer Ident. No.)

                    6531 NW 18th Court, Plantation, FL. 33313
                    (address of principal office)     (Zip Code)

                    Issuer's telephone number: (954) 581-9800

         Securities registered under Section 12(b) of the Exchange Act:
                                      None

         Securities registered under Section 12(g) of the Exchange Act:
                           Common Stock, no par value
                                (Title of class)

Indicate by check mark whether the Registrant:(1) has filed all reports required
to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. Yes __X_ No____ .


Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B not contained in this form, and no disclosure will be contained,
to the best of Registrants knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or
amendment to this Form 10-KSB. [ ]

State issuer's revenues for its most recent fiscal year. $184,085

Based on the average closing bid and asked prices of the common stock on the
latest practicable date, September 25, 2003, the aggregate market value of the
voting stock held by non-affiliates of the registrant was $170,976,288.

The number of shares outstanding of each of the issuer's classes of common
stock, as of September 25, 2003 was 166,025,887. As of September 25, 2003, the
issuer had no shares of preferred stock outstanding.

                       Documents Incorporated By Reference
                                     [None]


<PAGE>


                        IMAGING DIAGNOSTIC SYSTEMS, INC.
                          (a Development Stage Company)

                            Statements of Cash Flows

The Statement of Cash Flows is revised to correct typographical errors in the
lines for "(Increase) decrease in loans receivable - employees" and "(Increase)
decrease in other assets" which now reads as follows:



<TABLE>
<CAPTION>

                                                                                                   From
                                                                                                 Inception
                                                                                                (December 10,
                                                                 Year Ended      Year Ended      1993) to
                                                               June 30, 2003   June 30, 2002   June 30, 2003
                                                               ------------    ------------    ------------
<S>                                                                     <C>             <C>             <C>
Net loss                                                       $ (8,180,524)   $ (7,677,560)   $(61,996,562)
                                                               ------------    ------------    ------------
Adjustments to reconcile net loss to net cash
 used for operating activities:
    Depreciation and amortization                                   240,329         246,871       2,057,854
    Gain on sale of fixed assets                                    (11,254)           --           (11,254)
    Amortization of deferred compensation                              --              --         4,064,250
    Noncash interest, compensation and consulting expenses        1,827,425         805,555      15,343,110

    (Increase) decrease in loans receivable - employees                  16           6,930         (40,141)
    (Increase) decrease in inventory, net                           913,901        (120,992)      1,045,988
    (Increase) decrease in prepaid expenses                          27,985          (8,096)        (28,722)
    (Increase) decrease in other assets                             131,909         (52,697)       (306,618)

    Increase (decrease) in accounts payable and
      accrued expenses                                             (300,554)        446,928         971,385
    Increase (decrease) in other current liabilities               (178,250)       (262,200)      1,014,486
                                                               ------------    ------------    ------------


      Total adjustments                                           2,651,507       1,062,299      24,110,338
                                                               ------------    ------------    ------------

      Net cash used for operating activities                     (5,529,017)     (6,615,261)    (37,886,224)
                                                               ------------    ------------    ------------

Cash flows from investing activities:
    Proceeds from sale of property and equipment                     11,254            --            11,254
    Prototype equipment                                                --              --        (2,799,031)
    Capital expenditures                                            (43,314)        (78,055)     (4,072,236)
                                                               ------------    ------------    ------------

      Net cash used for investing activities                        (32,060)        (78,055)     (6,860,013)
                                                               ------------    ------------    ------------

Cash flows from financing activities:
    Repayment of capital lease obligation                              --            (4,056)        (50,289)
    Proceeds from convertible debenture                                --              --         3,240,000
    Proceeds from (repayments) loan payable, net                 (1,153,310)      1,100,000       2,595,029
    Proceeds from issuance of preferred stock                          --              --
                                                                                                 18,039,500
    Net proceeds from issuance of common stock                    7,881,000       5,585,000      22,283,504
                                                               ------------    ------------    ------------

      Net cash provided by financing activities                   6,727,690       6,680,944      46,107,744
                                                               ------------    ------------    ------------

Net increase in cash and cash equivalents                         1,166,613         (12,372)      1,361,507

Cash and cash equivalents at beginning of period                    194,894         207,266             -0-
                                                               ------------    ------------    ------------

Cash and cash equivalents at end of period                     $  1,361,507    $    194,894    $  1,361,507
                                                               ============    ============    ============


                                                                                                      (Continued)
</TABLE>




               See accompanying notes to the financial statements.


<PAGE>

                        IMAGING DIAGNOSTIC SYSTEMS, INC.
                          (a Development Stage Company)

                       Statement of Cash Flows (Continued)


<TABLE>
<CAPTION>

                                                                                                 From
                                                                                                 Inception
                                                                                                 (December 10,
                                                                Year Ended        Year Ended        1993) to
                                                              June 30, 2003     June 30, 2002    June 30, 2003
                                                              -------------     -------------    -------------
<S>                                                                 <C>              <C>                <C>
Supplemental disclosures of cash flow information:

         Cash paid for interest                               $       131,145   $     5,104      $     209,968
                                                              ===============   ============     =============

Supplemental disclosures of noncash investing
 and financing activities:

         Issuance of common stock and options
           in exchange for services                           $       841,853   $   176,750      $   5,856,350
                                                              ===============   =============    =============

         Issuance of common stock as loan fees in
           connection with loans to the Company               $       -         $      -         $     293,694
                                                              ===============   =============    =============

         Issuance of common stock as satisfaction of
           loans payable and accrued interest                 $       -         $      -         $   3,398,965
                                                              ===============   =============    =============

         Issuance of common stock as satisfaction of
           certain accounts payable                           $        -        $      -         $     257,892
                                                              ===============   =============    =============

         Issuance of common stock in
           exchange for property and equipment                $       -         $      -         $      89,650
                                                              ===============   =============    =============

         Issuance of common stock and other current liability
           in exchange for patent licensing agreement          $        -       $      -         $     581,000
                                                              ===============   =============    =============

         Issuance of common stock for
           compensation                                       $       128,800   $   117,600      $   2,194,988
                                                              ===============   =============    =============

         Issuance of common stock through
           exercise of incentive stock options                $        -        $      -         $   3,117,702
                                                              ===============   =============    =============

         Issuance of common stock as
           payment for preferred stock dividends              $        -        $      -         $     507,645
                                                              ===============   =============    =============

         Acquisition of property and equipment
           through the issuance of a capital
           lease payable                                      $        -        $      -         $      50,289
                                                              ===============   =============    =============





</TABLE>


               See accompanying notes to the financial statements.



<PAGE>





                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, Imaging Diagnostic Systems, Inc. has duly caused this
amendment to be signed on our behalf by the undersigned, thereunto duly
authorized,


                      IMAGING DIAGNOSTIC SYSTEMS, INC.


                             By:  /s/Linda B. Grable
                                  ------------------
                                  Linda B. Grable, Chairman of the Board and
                                  Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this
amendment has been signed by the following persons in the capacities and on the
dates indicated.

<TABLE>
<CAPTION>

Signatures                  Title                                   Date
----------                  -----                                   ----
<S>                          <C>                                    <C>

/s/Linda B. Grable         Chairman of the Board and Chief          November 6, 2003
------------------
Linda B. Grable            Executive Officer

/s/Allan L. Schwartz       Director, Executive Vice President       November 6, 2003
--------------------
Allan L. Schwartz          (Principal Accounting and Financial
                           Officer)

</TABLE>